Skip to main content
Clinical Trials/CTRI/2019/01/017272
CTRI/2019/01/017272
Active, not recruiting
Phase 4

Efficacy of an integrated approach encompassing pregabalin and mirror therapy in management of complex regional pain syndrome type 1- A pilot study.

niversity College of Medical Sciences0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: - Health Condition 2: G63- Polyneuropathy in diseases classified elsewhere
Sponsor
niversity College of Medical Sciences
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
niversity College of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • Patients having chronic continuous pain, which is disproportionate to any inciting event with diagnosis of CRPS type 1, as confirmed by\-
  • Budapest criteria of CRPS for clinical use (IASP 2016\)
  • Must report at least one symptom in three of the four following categories:
  • Sensory: reports of hyperesthesia and/or allodynia
  • Vasomotor: reports of temperature asymmetry and/or skin color changes and/or skin color asymmetry.
  • Sudomotor: reports of edema and/or sweating changes and/or sweating asymmetry.
  • Motor/trophic: reports of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nails, skin).
  • Must display at least one sign at the time of evaluation in two or more of the following four categories:
  • Sensory: Evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch and/or deep somatic pressure, allodynia to innocuous cold (25 â?¦C) or innocuous warm (40 â?¦C), and/or joint movement).
  • Vasomotor: evidence of temperature asymmetry and/or skin color changes and/or skin color asymmetry.

Exclusion Criteria

  • The presence of pain at any other site due to any other cause.
  • An intra\-articular injection into the joints during the previous 6 months or use of systemic corticosteroids during the previous 4 months;
  • Uncontrolled co\-morbid medical conditions;
  • Cognitive impairments that might interfere with understanding instructions for various questionnaires, motor testing, and treatment.

Outcomes

Primary Outcomes

Not specified

Similar Trials